“US Doctors Use CRISPR to Cure Rare Liver Disorder in 9-Month-Old Baby”

In a historic milestone for precision medicine, doctors in the United States have successfully used a customised CRISPR-based gene-editing therapy to treat a nine-month-old infant suffering from a rare and life-threatening liver disorder. Baby KJ, diagnosed with carbamoyl phosphate synthetase 1 (CPS1) deficiency, became the first person in the world to receive a personalised DNA correction specifically designed to address his unique genetic mutation. The breakthrough, achieved by a team at the Children’s Hospital of Philadelphia (CHOP) and Penn Medicine, marks a revolutionary step in the treatment of ultra-rare genetic diseases.

Why in News?

A nine-month-old baby, KJ Muldoon, suffering from a rare genetic liver disorder, became the first person in the world to receive a personalized CRISPR-based gene-editing therapy. Developed by researchers at the Children’s Hospital of Philadelphia (CHOP) and Penn Medicine, this pioneering treatment marks a milestone in precision medicine and offers new hope for patients with rare, untreatable genetic conditions.

Key Highlights

• Patient: KJ Muldoon, a 9-month-old infant from the United States
• Condition: CPS1 deficiency – a rare, life-threatening liver disorder
• Treatment: Personalized CRISPR-based gene editing, specifically base editing
• Delivery method: Lipid nanoparticles targeting the liver
• Institutions involved: Children’s Hospital of Philadelphia (CHOP) and Penn Medicine
• Doctors leading the research: Dr. Kiran Musunuru and Dr. Rebecca Ahrens-Nicklas
• Outcome: Significant improvement in KJ’s health with no severe side effects reported

Background on CPS1 Deficiency

• CPS1 (Carbamoyl Phosphate Synthetase 1) deficiency is an inherited urea cycle disorder.
• The liver fails to convert toxic ammonia into urea, leading to dangerous ammonia accumulation.
• This condition can cause brain damage or death within days of birth if left untreated.
• Standard treatments include protein-restricted diets, medications, and in some cases, liver transplants.

How CRISPR Was Used

• CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) is a gene-editing tool that enables scientists to modify DNA with high precision.
• The treatment for KJ used base editing, a technique that changes a single letter of DNA without cutting the strand.
• This precision is especially useful in treating rare, one-off genetic mutations like the one affecting KJ.
• The therapy was developed, tested, and administered within six months of diagnosis.
• Significance of the Achievement
• First-of-its-kind therapy tailored to an individual patient’s mutation.
• Demonstrates the real-time application of gene editing in personalized medicine.
• Potential to create a framework for treating other rare disorders with similar customization.
• Minimizes reliance on lifelong medications or invasive surgeries like transplants.
• Offers a blueprint for researchers globally to replicate such models.

Summary/Static	Details
Why in the news?	“US Doctors Use CRISPR to Cure Rare Liver Disorder in 9-Month-Old Baby”
Patient	KJ Muldoon, 9-month-old infant
Disorder	CPS1 deficiency (urea cycle disorder)
Therapy Used Personalized	CRISPR-based base editing
Institutions Involved	CHOP and Penn Medicine
Outcome	Improved protein tolerance, reduced medication, no major side effects
Global Significance	Opens doors for precision medicine in rare diseases